A Phase 3 clinical trial involving cagrilintide, as part of the CagriSema combination, has reached completed status as of September 30, 2026. The trial, registered as NCT06323174, is titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise." It was designed to evaluate CagriSema against placebo in people with type 2 diabetes managed through diet and exercise. The study status is listed as completed, and the trial phase is Phase 3.
No results, outcomes, or efficacy data are included in this update. The completion status reflects the trial's conduct timeline, not any findings about blood sugar or body weight changes. Cagrilintide remains an unapproved compound under research status, and CagriSema is being studied for its combined effects in this population.
Readers should note that trial completion indicates the study has concluded data collection or related activities, not that results have been published or reviewed. Further updates may follow as findings from this trial become available through official channels.
For more background on cagrilintide and its research status, see the compound overview.